Infectious Disease Clinical Trials Update: Week 16, 2026

Published April 17, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

This Phase 3 trial is testing updated COVID-19 vaccines designed to protect against new variants in children from 6 months to under 12 years old. The goal is to find vaccines that are both safe and effective at triggering a strong immune response. If successful, this could lead to better vaccine options tailored for children, helping to keep them safer as the virus changes.

Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in Chad

This Phase 4 study is comparing two ways to give the R21/MM malaria vaccine to young children in Chad, where malaria rates are high during certain seasons. By finding the best vaccine schedule, this research could improve how malaria prevention is done alongside other seasonal efforts. This might reduce the number of malaria cases and serious illness in young children in affected areas.

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

This Phase 3 trial focuses on adults aged 50 to 64 to see how well a COVID-19 vaccine protects them compared to a placebo. The study aims to provide more options for preventing COVID-19 in this age group, which can be more vulnerable to severe illness. Although the trial is no longer recruiting, ongoing analysis may lead to new vaccination choices for middle-aged adults.

Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence

This large study looked at starting HIV treatment immediately after diagnosis versus following South African guidelines that delay treatment based on immune status. The findings will help understand if starting treatment right away can reduce HIV spread in communities. Results from over 28,000 participants will inform future public health policies and HIV care practices.

Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents

This Phase 2 study is evaluating a new vaccine that protects against five types of meningococcal bacteria in healthy teenagers. Researchers are testing different dosing schedules to find the safest and most effective way to build immunity. If successful, this vaccine could provide broader protection against meningitis, a serious infection that can cause long-term health problems.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.